Although malaria vaccines based on DNA or adenoviruses alone have been immunogenic, eliciting robust CD8+ T cell responses, they have demonstrated sub-optimal protection in CHMI studies [3–5], while heterologous prime-boost strategies have proven more immunogenic and protective [6–9]. The gene discussed is CD8A; the disease is malaria.